NASDAQ:AVXL - Anavex Life Sciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.60
  • Forecasted Upside: 51.72 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$11.60
▼ -0.2 (-1.69%)
1 month | 3 months | 12 months
Get New Anavex Life Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AVXL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AVXL

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$17.60
▲ +51.72% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Anavex Life Sciences in the last 3 months. The average price target is $17.60, with a high forecast of $25.00 and a low forecast of $10.00. The average price target represents a 51.72% upside from the last price of $11.60.
Buy
The current consensus among 5 contributing investment analysts is to buy stock in Anavex Life Sciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/23/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/21/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/19/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/20/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/1/2021Cantor FitzgeraldReiterated RatingOverweight$10.00 ➝ $25.00N/A
i
2/23/2021Cantor FitzgeraldBoost Price TargetOverweight$10.00 ➝ $25.00High
i
2/17/2021LADENBURG THALM/SH SHReiterated RatingBuy$20.00Low
i
12/16/2020HC WainwrightBoost Price TargetPositive ➝ Buy$14.00 ➝ $17.00N/A
i
10/21/2020HC WainwrightBoost Price TargetBuy$12.00 ➝ $14.00Low
i
Rating by Ram Selvaraju at HC Wainwright
9/28/2020LADENBURG THALM/SH SHInitiated CoverageBuy$12.00High
i
8/11/2020HC WainwrightReiterated RatingBuyLow
i
Rating by Ram Selvaraju at HC Wainwright
6/16/2020HC WainwrightReiterated RatingBuy$12.00High
i
Rating by Ram Selvaraju at HC Wainwright
6/8/2020Dawson JamesReiterated RatingBuy$16.00Medium
i
6/8/2020Janney Montgomery ScottReiterated RatingBuy$10.00Medium
i
6/8/2020Cantor FitzgeraldReiterated RatingBuy$8.00Medium
i
Rating by C. Duncan at Cantor Fitzgerald
6/5/2020HC WainwrightReiterated RatingBuy$12.00High
i
Rating by Ram Selvaraju at HC Wainwright
5/22/2020HC WainwrightReiterated RatingBuy$12.00Low
i
Rating by R. Selvaraju at HC Wainwright
5/8/2020HC WainwrightReiterated RatingBuy$12.00High
i
Rating by R. Selvaraju at HC Wainwright
4/1/2020HC WainwrightReiterated RatingBuy$12.00High
i
Rating by R. Selvaraju at HC Wainwright
3/16/2020HC WainwrightInitiated CoverageBuy$12.00Medium
i
Rating by R. Selvaraju at HC Wainwright
2/26/2020Cantor FitzgeraldInitiated CoverageOverweightHigh
i
Rating by C. Duncan at Cantor Fitzgerald
7/24/2019Dawson JamesInitiated CoverageBuy$16.00Low
i
Rating by J. Kolbert at Dawson James
6/18/2019Janney Montgomery ScottInitiated CoverageBuy ➝ Buy$10.00High
i
5/23/2019Roth CapitalReiterated RatingBuyMedium
i
Rating by S. Henry at Roth Capital
2/8/2019Roth CapitalSet Price TargetBuy$10.00High
i
Rating by Jotin Marango at Roth Capital
1/28/2019Roth CapitalInitiated CoverageBuy$10.00Low
i
Rating by J. Marango at Roth Capital
12/13/2018Maxim GroupSet Price TargetBuy$7.00High
i
Rating by Caroline Palomeque at Maxim Group
10/31/2018HC WainwrightSet Price TargetBuy$10.00Low
i
Rating by Jason Kolbert at HC Wainwright
10/26/2018Maxim GroupSet Price TargetBuy$7.00Medium
i
Rating by Caroline Palomeque at Maxim Group
10/22/2018HC WainwrightReiterated RatingBuy$10.00High
i
Rating by Jason Kolbert at HC Wainwright
10/19/2018Maxim GroupSet Price TargetBuy$7.00High
i
Rating by Caroline Palomeque at Maxim Group
8/28/2018Maxim GroupSet Price TargetBuy$7.00Low
i
Rating by Caroline Palomeque at Maxim Group
8/28/2018HC WainwrightSet Price TargetBuy$10.00Medium
i
Rating by Jason Kolbert at HC Wainwright
8/10/2018HC WainwrightSet Price TargetBuy$10.00High
i
Rating by Jason Kolbert at HC Wainwright
8/9/2018Maxim GroupReiterated RatingBuy$7.00Low
i
Rating by Caroline Palomeque at Maxim Group
7/25/2018HC WainwrightSet Price TargetBuy$10.00High
i
Rating by Jason Kolbert at HC Wainwright
7/10/2018HC WainwrightSet Price TargetBuy$10.00Low
i
Rating by Jason Kolbert at HC Wainwright
7/9/2018Maxim GroupInitiated CoverageBuy$7.00Low
i
Rating by Caroline Palomeque at Maxim Group
7/3/2018Maxim GroupInitiated CoverageBuy$7.00Low
i
Rating by Caroline Palomeque at Maxim Group
7/3/2018HC WainwrightSet Price TargetBuy$10.00High
i
Rating by Jason Kolbert at HC Wainwright
5/31/2018Maxim GroupReiterated RatingBuy$5.00 ➝ $7.00Low
i
Rating by Caroline Palomeque at Maxim Group
5/30/2018HC WainwrightInitiated CoverageBuy$10.00High
i
Rating by J. Kolbert at HC Wainwright
5/16/2018Noble FinancialSet Price TargetBuy$7.00High
i
Rating by Caroline Palomeque at Noble Financial
5/16/2018Maxim GroupInitiated CoverageBuy$5.00 ➝ $7.00High
i
Rating by Jason Kolbert at Maxim Group
3/8/2018Roth CapitalInitiated CoverageBuy ➝ Buy$6.00High
i
Rating by R. Leboyer at Roth Capital
2/21/2018Noble FinancialReiterated RatingBuyLow
i
Rating by Caroline Palomeque at Noble Financial
2/14/2018Maxim GroupSet Price TargetBuy$5.00Low
i
Rating by Jason Kolbert at Maxim Group
2/8/2018Maxim GroupSet Price TargetBuy ➝ Buy$14.00 ➝ $5.00Low
i
Rating by Jason Kolbert at Maxim Group
12/12/2017Noble FinancialReiterated RatingBuyMedium
i
Rating by Caroline Palomeque at Noble Financial
12/11/2017Maxim GroupSet Price TargetBuy$14.00High
i
Rating by Jason Kolbert at Maxim Group
10/30/2017Maxim GroupSet Price TargetBuy$15.00N/A
i
Rating by Jason Kolbert at Maxim Group
10/12/2017Maxim GroupSet Price TargetBuy$15.00N/A
i
Rating by Jason Kolbert at Maxim Group
9/29/2017Noble FinancialReiterated RatingBuy ➝ Buy$15.00Low
i
Rating by Kumaraguru Raja at Noble Financial
8/9/2017Noble FinancialReiterated RatingBuyHigh
i
Rating by Mark Jordan at Noble Financial
8/7/2017Maxim GroupSet Price TargetBuy$15.00Low
i
Rating by Jason Kolbert at Maxim Group
7/20/2017Maxim GroupReiterated RatingBuy$15.00High
i
Rating by Jason McCarthy at Maxim Group
5/22/2017Maxim GroupSet Price TargetBuy$15.00Low
i
Rating by Jason McCarthy at Maxim Group
5/14/2017Noble FinancialReiterated RatingBuyLow
i
Rating by Mark Jordan at Noble Financial
4/9/2017Noble FinancialReiterated RatingBuyHigh
i
2/7/2017Noble FinancialInitiated CoverageBuy$16.00N/A
i
1/19/2017Maxim GroupSet Price TargetBuy$15.00N/A
i
Rating by Jason McCarthy at Maxim Group
11/29/2016Maxim GroupReiterated RatingBuy$15.00N/A
i
Rating by Jason Kolbert at Maxim Group
10/10/2016Maxim GroupReiterated RatingBuy$15.00N/A
i
Rating by Jason Kolbert at Maxim Group
10/5/2016(FBRC)Reiterated RatingOutperform$10.00N/A
i
Rating by Christopher James at (FBRC)
9/29/2016(FBRC)Set Price TargetBuy$10.00N/A
i
Rating by Christopher James at (FBRC)
9/23/2016(FBRC)Reiterated RatingOutperform$10.00N/A
i
Rating by Christopher James at (FBRC)
8/15/2016(FBRC)Reiterated RatingOutperform$10.00N/A
i
Rating by Christopher James at (FBRC)
8/3/2016(FBRC)Reiterated RatingOutperform$10.00N/A
i
Rating by Christopher James at (FBRC)
7/27/2016Maxim GroupSet Price TargetBuy$15.00N/A
i
Rating by Jason Kolbert at Maxim Group
7/26/2016(FBRC)Reiterated RatingOutperform$10.00N/A
i
Rating by Christopher James at (FBRC)
6/22/2016Maxim GroupReiterated RatingBuy$15.00N/A
i
Rating by Jason Kolbert at Maxim Group
6/22/2016(FBRC)Reiterated RatingBuyN/A
i
Rating by Christopher James at (FBRC)
6/6/2016Maxim GroupReiterated RatingBuyN/A
i
Rating by Jason Kolbert at Maxim Group
5/20/2016Maxim GroupReiterated RatingBuy$15.00N/A
i
Rating by Jason Kolbert at Maxim Group
5/12/2016(FBRC)Reiterated RatingBuyN/A
i
Rating by Christopher James at (FBRC)
5/11/2016Maxim GroupReiterated RatingBuy$15.00N/A
i
Rating by Jason Kolbert at Maxim Group
4/25/2016Maxim GroupReiterated RatingPositive$15.00N/A
i
Rating by Jason Kolbert at Maxim Group
(Data available from 4/19/2016 forward)
Anavex Life Sciences logo
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
Read More

Today's Range

Now: $11.60
$11.25
$12.08

50 Day Range

MA: $14.06
$11.73
$16.13

52 Week Range

Now: $11.60
$3.01
$28.70

Volume

24,595 shs

Average Volume

3,635,298 shs

Market Capitalization

$812.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.7

Frequently Asked Questions

What sell-side analysts currently cover shares of Anavex Life Sciences?

The following Wall Street research analysts have issued research reports on Anavex Life Sciences in the last twelve months: Cantor Fitzgerald, Dawson James, HC Wainwright, Janney Montgomery Scott, LADENBURG THALM/SH SH, and Zacks Investment Research.
View the latest analyst ratings for AVXL.

What is the current price target for Anavex Life Sciences?

5 Wall Street analysts have set twelve-month price targets for Anavex Life Sciences in the last year. Their average twelve-month price target is $17.60, suggesting a possible upside of 49.2%. Cantor Fitzgerald has the highest price target set, predicting AVXL will reach $25.00 in the next twelve months. Janney Montgomery Scott has the lowest price target set, forecasting a price of $10.00 for Anavex Life Sciences in the next year.
View the latest price targets for AVXL.

What is the current consensus analyst rating for Anavex Life Sciences?

Anavex Life Sciences currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AVXL will outperform the market and that investors should add to their positions of Anavex Life Sciences.
View the latest ratings for AVXL.

What other companies compete with Anavex Life Sciences?

How do I contact Anavex Life Sciences' investor relations team?

Anavex Life Sciences' physical mailing address is 51 W 52ND STREET 7TH FLOOR, NEW YORK NY, 10019. The biotechnology company's listed phone number is (800) 689-3939 and its investor relations email address is [email protected] The official website for Anavex Life Sciences is www.anavex.com.